Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by Mark Stroh
Exposure–Response and Tumor Growth Inhibition Analyses of the Monovalent Anti-C-Met Antibody Onartuzumab (MetMAb) in the Second- And Third-Line Non-Small Cell Lung Cancer
AAPS Journal
Pharmaceutical Science
Related publications
Monovalent Antibody Design and Mechanism of Action of Onartuzumab, a MET Antagonist With Anti-Tumor Activity as a Therapeutic Agent
Proceedings of the National Academy of Sciences of the United States of America
Multidisciplinary
Treatment Paradigms for Patients With Metastatic Non-Small-Cell Lung Cancer: First-, Second-, and Third-Line
Current Oncology
Oncology
The Persistent Promise of Combining HGF/MET and EGFR Inhibition in Non-Small Cell Lung Cancer
Cancer
Cancer Research
Oncology
Aggregation of Lipid Rafts Activates C-Met and C-SRC in Non-Small Cell Lung Cancer Cells
BMC Cancer
Cancer Research
Oncology
Genetics
Comparison of Primary Tumor SUVmax Between Small Cell Lung Cancer and Non-Small Cell Lung Cancer
Current Trends in Clinical & Medical Imaging
Tumor Evolution in Non-Small-Cell Lung Cancer
ESMO Open
Cancer Research
Oncology
Pharmacoeconomic Study of Pembrolizumab and Nivolumab in the Second Line of Therapy of Advanced Non-Small Cell Lung Cancer
Effective Pharmacotherapy
Second-Line Treatment of Non-Small Cell Lung Cancer: Focus on the Clinical Development of Dacomitinib
Frontiers in Medicine
Medicine
P1.04-29 Second or Third Line Nivolumab Versus First Line Nivolumab in Patients With Previously Treated Advanced Non Small Cell Lung Cancer (NSCLC)
Journal of Thoracic Oncology
Medicine
Oncology
Respiratory Medicine
Pulmonary
